Hartmann's Solution

Adult administration

For adults, a single dose of 500–1,000mL is administered by slow intravenous infusion. The administration rate is 300–500mL per hour (75–120 drops per minute). The dosage and administration rate should be adjusted according to age, weight, and symptoms.

When used with intravenous calcium-containing preparations, this medication can form precipitates if mixed with ceftriaxone, so it should not be administered simultaneously with the same infusion device. Allergic reactions may occur while using this medication; therefore, if any hypersensitivity symptoms arise, administration should be stopped immediately, and appropriate treatment should be received. Since this medication contains potassium, there is a risk of hyperkalemia, which is elevated blood potassium levels. Patients with impaired kidney function or heart diseases should be particularly cautious and may need to frequently check blood potassium levels as necessary. This medication can cause hypernatremia and hyperchloremia, where sodium and chloride levels increase, and symptoms related to fluid overload may present. Therefore, patients with related conditions should use it cautiously. Additionally, hyponatremia, which is low blood sodium levels, may occur, particularly in children, the elderly, and postoperative patients, necessitating careful monitoring, as severe symptoms can pose a risk of brain damage. Hypercalcemia, which is elevated calcium levels, may also be induced, thus it should be avoided in patients with calcium kidney stones or those at risk of hypercalcemia. This medication can affect the body's fluid and electrolyte balance, and symptoms such as fluid overload or pulmonary edema may occur during administration, hence careful observation and monitoring of the patient's condition are required. It should not be administered to patients with lactic acidosis, fluid overload, hypernatremia, or known hypersensitivity to this medication. In patients with severely impaired kidney function, heart failure, or severe liver dysfunction, it should be administered with caution, and blood tests and fluid status should be closely monitored during administration. Rapid or large-volume administration of this medication may lead to side effects such as cerebral edema, pulmonary edema, and peripheral edema, so caution is advised. When used with other medications, interactions should be carefully considered, particularly when combined with drugs that can induce or worsen hyperkalemia, hyponatremia, or hypercalcemia should be approached with greater caution. During pregnancy, this medication should be used only when necessary, considering the risks to the fetus, and in children and the elderly, the administration rate should be adjusted, and serum electrolyte levels should be frequently monitored. Prior to administration, the patient's skin and equipment should be disinfected to prevent infections, the solution should be warmed to body temperature for use, and it should be administered immediately after opening. The administration rate should be slowly injected into the vein, and storage should be at room temperature.

Serious side effects

Hives, anaphylaxis (severe allergic reaction), dyspnea, pulmonary edema, peripheral edema, hyperkalemia (risk of cardiac arrest), hyponatremia (headache, seizures, drowsiness), cerebral edema, cardiac arrest.

Mild side effects

• Vomiting
• hypertension
• tachycardia
• chills
• fever
• generalized rash and erythema
• rash
• electrolyte imbalance
• fluid overload
• hyponatremic encephalopathy

This medication should be stored in a sealed container to prevent air and moisture exposure. It is advisable to maintain a storage temperature between 1°C and 30°C at room temperature.

Appearance

A colorless, transparent liquid contained in a polypropylene, multilayer film plastic container.

Package unit

500mL/bag, 1000mL/bag